The research of the application of a new urinary biomarker PCA-M of prostate cancer (PSA from 4 to 20 ng/ml)

References

• Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. 2016. Cancer statistics in China, 2015. CA Cancer J Clin. 66(2):115–132. doi:10.3322/caac.21338. Epub 2016/01/26. PubMed PMID: 26808342.
   PubMed Web of Science ®Google Scholar
• Cuzick J, Thorat MA, Andriole G, Brawley OW, Brown PH, Culig Z, Eeles RA, Ford LG, Hamdy FC, Holmberg L, et al. 2014. Prevention and early detection of prostate cancer. Lancet Oncol. 15(11):e484–e492. doi:10.1016/s1470-2045(14)70211-6. Epub 2014/10/05. PubMed PMID: 25281467; PubMed Central PMCID: PMCPMC4203149.
   PubMed Web of Science ®Google Scholar
• Daniunaite K, Jarmalaite S, Kalinauskaite N, Petroska D, Laurinavicius A, Lazutka JR, Jankevicius F. 2014. Prognostic value of RASSF1 promoter methylation in prostate cancer. J Urol. 192(6):1849–1855. doi:10.1016/j.juro.2014.06.075. Epub 2014 Jun 26. PMID: 24980613.
   PubMed Web of Science ®Google Scholar
• Day JR, Jost M, Reynolds MA, Groskopf J, Rittenhouse H. 2011. PCA3: from basic molecular science to the clinical lab. Cancer Lett. 301(1):1–6. doi:10.1016/j.canlet.2010.10.019. Epub 2010/11/26. PubMed PMID: 21093148.
   PubMed Web of Science ®Google Scholar
• Eapen RS, Nzenza TC, Murphy DG, Hofman MS, Cooperberg M, Lawrentschuk N. 2019. PSMA PET applications in the prostate cancer journey: from diagnosis to theranostics. World J Urol. 37(7):1255–1261. doi:10.1007/s00345-018-2524-z. Epub 2018/10/31. PubMed PMID: 30374609.
   PubMed Web of Science ®Google Scholar
• Fujita K, Landis P, McNeil BK, Pavlovich CP. 2009. Serial prostate biopsies are associated with an increased risk of erectile dysfunction in men with prostate cancer on active surveillance. J Urol. 182(6):2664–2669. doi:10.1016/j.juro.2009.08.044. Epub 2009/10/20. PubMed PMID: 19836757.
   PubMed Web of Science ®Google Scholar
• Fujita K, Nonomura N. 2018. Urinary biomarkers of prostate cancer. Int J Urol. 25(9):770–779. doi:10.1111/iju.13734. Epub 2018/08/22. PubMed PMID: 30129068.
   PubMed Web of Science ®Google Scholar
• Goessl C, Müller M, Heicappell R, Krause H, Straub B, Schrader M, Miller K. 2001. DNA-based detection of prostate cancer in urine after prostatic massage. Urology. 58(3):335–338. doi:10.1016/s0090-4295(01)01268-7. PMID: 11549474.
   PubMed Web of Science ®Google Scholar
• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. 2011. Global cancer statistics. CA Cancer J Clin. 61(2):69–90. doi:10.3322/caac.20107. Epub 2011/02/08. PubMed PMID: 21296855.
   PubMed Web of Science ®Google Scholar
• Kitagawa Y, Ueno S, Izumi K, Kadono Y, Konaka H, Mizokami A, et al. 2014. Cumulative probability of prostate cancer detection in biopsy according to free/total PSA ratio in men with total PSA levels of 2.1-10.0 ng/ml at population screening. J Cancer Res Clin Oncol. 140(1):53–59. doi:10.1007/s00432-013-1543-9. Epub 2013/10/30. PubMed PMID: 24165867.
   PubMed Web of Science ®Google Scholar
• Kretschmer A, Tilki D. 2017. Biomarkers in prostate cancer - current clinical utility and future perspectives. Crit Rev Oncol Hematol. 120:180–193. doi:10.1016/j.critrevonc.2017.11.007. Epub 2017/12/05. PubMed PMID: 29198331.
   PubMed Web of Science ®Google Scholar
• Li M, Zhou D, Zhang W, Gao S, Zhou X. 2018. Urine PCA3 mRNA level in diagnostic of prostate cancer. J Cancer Res Ther. 14(4):864–866. doi:10.4103/jcrt.JCRT_734_17. Epub 2018/07/05. PubMed PMID: 29970667.
   PubMed Web of Science ®Google Scholar
• Lin YR, Wei XH, Uhlman M, Lin XT, Wu SF, Diao PF, Xie HQ, Xie KJ, Tang P. 2015. PSA density improves the rate of prostate cancer detection in Chinese men with a PSA between 2.5-10.0 ng ml (-1) and 10.1-20.0 ng ml (-1): a multicenter study. Asian J Androl. 17(3):503–507. doi:10.4103/1008-682x.142129. Epub 2014/12/06. PubMed PMID: 25475661; PubMed Central PMCID: PMCPMC4430959.
   PubMed Web of Science ®Google Scholar
• Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, Jemal A, Kramer JL, Siegel RL. 2019. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 69(5):363–385. doi:10.3322/caac.21565. Epub 2019/06/12. PubMed PMID: 31184787.
   PubMed Web of Science ®Google Scholar
• Nguyen-Nielsen M, Borre M. 2016. Diagnostic and therapeutic strategies for prostate cancer. Semin Nucl Med. 46(6):484–490. doi:10.1053/j.semnuclmed.2016.07.002. Epub 2016/11/09. PubMed PMID: 27825428.
   PubMed Web of Science ®Google Scholar
• Oderda M, Marra G, Albisinni S, Altobelli E, Baco E, Beatrici V, Cantiani A, Carbone A, Ciccariello M, Descotes JL, et al. 2018. Accuracy of elastic fusion biopsy in daily practice: results of a multicenter study of 2115 patients. Int J Urol. 25(12):990–997. doi:10.1111/iju.13796. Epub 2018/09/07. PubMed PMID: 30187529.
   PubMed Web of Science ®Google Scholar
• Sebesta EM, Anderson CB. 2017. The surgical management of prostate cancer. Semin Oncol. 44(5):347–357. doi:10.1053/j.seminoncol.2018.01.003. Epub 2018/03/28. PubMed PMID: 29580436.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. 2016. Cancer statistics, 2016. CA Cancer J Clin. 66(1):7–30. doi:10.3322/caac.21332. Epub 2016/01/09. PubMed PMID: 26742998.
   PubMed Web of Science ®Google Scholar
• Yao L, Ren S, Zhang M, Du F, Zhu Y, Yu H, Zhang C, Li X, Yang C, Liu H, et al. 2015. Identification of specific DNA methylation sites on the Y-chromosome as biomarker in prostate cancer. Oncotarget. 6(38):40611–40621. doi:10.18632/oncotarget.6141. Epub 2015/10/21. PubMed PMID: 26485765; PubMed Central PMCID: PMCPMC4747356.
   PubMedGoogle Scholar
• Zhu Y, Han CT, Zhang GM, Liu F, Ding Q, Xu JF, Vidal AC, Freedland SJ, Ng CF, Ye DW. 2015. Development and external validation of a prostate health index-based nomogram for predicting prostate cancer. Sci Rep. 5:15341. doi:10.1038/srep15341. Epub 2015/10/17. PubMed PMID: 26471350; PubMed Central PMCID: PMCPMC4607975.
   PubMed Web of Science ®Google Scholar